# BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
Canonical URL: https://biopharmsignal.com/news/BCDA/biocardia-to-host-2025-financial-results-and-corporate-update-conference-call-on-35a2dfa4
Ticker: BCDA
Company: BioCardia
Source: BioCardia
Published: 2026-03-19 23:47 EST
## Summary

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

## Article Body
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360 .

Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=5Vq7aAhd

A webcast replay of the call will be available approximately one hour after the end of the call through approximately June 24, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html . A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 7756290.

About BioCardia® BioCardia, Inc. , headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com .

MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120

INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
## Recent Company News
- 2026-06-18 12:00 EST — [BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities](https://biopharmsignal.com/news/BCDA/biocardia-letter-to-stockholders-on-2026-priorities-and-strategic-opportunities-187b0df4) — Source: BioCardia
- 2026-06-08 12:00 EST — [BioCardia Announces $4.4 Million Financing](https://biopharmsignal.com/news/BCDA/biocardia-announces-4-4-million-financing-0937a2f3) — Source: BioCardia
- 2026-06-05 12:00 EST — [FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF](https://biopharmsignal.com/news/BCDA/fda-confirms-cardiamp-hf-ii-may-support-premarket-approval-of-cardiamp-cell-ther-336b7f77) — Source: BioCardia
- 2026-05-28 12:00 EST — [BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure](https://biopharmsignal.com/news/BCDA/biocardia-announces-japan-pmda-record-of-advice-supports-regulatory-submission-f-6bb5419d) — Source: BioCardia
- 2026-05-21 12:00 EST — [BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency](https://biopharmsignal.com/news/BCDA/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-fd6856cf) — Source: BioCardia
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)